Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acticor Biotech Completes Interim Futility Analysis in the GREEN Study
Details : ACT-017 (glenzocimab) is a GPVI inhibitor antibody, which is being evaluated as an adjunct to mechanical thrombectomy in the first 24 hours of acute ischemic stroke.
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
July 26, 2024
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly i...
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
September 14, 2023
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly i...
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target, platelet glycoprotein VI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly i...
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TOTUM•854, a patented active substance based on a combination of plant extracts, is developed to reduce blood pressure in people with mild to moderate hypertension, by reducing angiotensin I-converting enzyme (ACE1) activity.
Product Name : TOTUM•854
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022
Details : ACT017 (glenzocimab), humanized mAB fragment directed against a novel target of major interest, platelet glycoprotein VI, inhibits platelet binding to thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly i...
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
September 05, 2022
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT017 (glenzocimab), a humanized mAb fragment directed against a novel target of major interest, platelet GPVI. Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particu...
Product Name : ACT017
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Glenzocimab
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : University of Avignon
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results, obtained in vivo on models predictive of hypertension in humans, showed that TOTUM•854 is effective in preventing hypertension.
Product Name : TOTUM•854
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 04, 2021
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : University of Avignon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : University of Avignon
Deal Size : Inapplicable
Deal Type : Inapplicable
VALBIOTIS Selected to Present TOTUM-854’s Results
Details : Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Rio...
Product Name : TOTUM•854
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 03, 2021
Lead Product(s) : TOTUM•854
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : University of Avignon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Faran
Deal Size : Undisclosed
Deal Type : Collaboration
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Details : Under the terms of the agreement, Faran will receive the exclusive rights to market Firibastat for the treatment of difficult-to-treat / resistant hypertension in Greece.
Product Name : QGC001
Product Type : Other Small Molecule
Upfront Cash : $12.1 million
December 15, 2020
Lead Product(s) : Firibastat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Faran
Deal Size : Undisclosed
Deal Type : Collaboration